Multiple myeloma biology: Lessons from the 5TMM models

Immunological Reviews

Volumn 194, Issue , 2003, Pages 196-206

  Vanderkerken, Karin ^a   Asosingh, Kewal ^a   Croucher, Peter ^b   Van Camp, Ben ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b NUFFIELD ORTHOPAEDIC CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CD45 ANTIGEN; HYBRID PROTEIN; LAMININ 1; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ANGIOGENESIS; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; B LYMPHOCYTE; BONE DISEASE; BONE MARROW CELL; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSFER; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE ASSOCIATION; ELDERLY CARE; GENE SWITCHING; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IN VIVO STUDY; ISOGRAFT; MICROENVIRONMENT; MOLECULAR BIOLOGY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OSTEOLYSIS; PLASMA CELL; PRIORITY JOURNAL; PROCESS MODEL; PROTEIN TARGETING; REVIEW; STATISTICAL SIGNIFICANCE; SURVIVAL; THREE DIMENSIONAL IMAGING;

ANIMALS; ANTIGENS, CD45; BONE AND BONES; BONE MARROW CELLS; CELL MOVEMENT; DISEASE MODELS, ANIMAL; HUMANS; MULTIPLE MYELOMA;

EID: 0041814539     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2003.00035.x     Document Type: Review

References (64)

1. Asosingh K, Radl J, Van Riet I, Van Camp B, Vanderkerken K. The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J 2000;1:351-356.
2. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 1998;92:2908-2913.
3. Avet-Loiseau H, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002;99:2185-2191.
4. Radl J. Age-related monoclonal gammapathies: clinical lessons from the aging C57BL mouse. Immunol Today 1990;11:234-236.
5. Radl J, De Glopper ED, Schuit HR, Zurcher C. Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol 1979;122:609-613.
6. Vanderkerken K, Goes E, De Raeve H, Radl J, Van Camp B. Follow-up of bone lesions in an experimental multiple myeloma mouse model: description using X-ray dedicated for mammography. Br J Cancer 1996;73:1463-1465.
7. Vanderkerken K, et al. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer 1997;76:451-460.
8. Croucher PI, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001;98:3534-3540.
9. Van Valckenborgh E, et al. Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo. Br J Cancer 2002;86:796-802.
10. Van Riet I, Heirman C, Lacor P, De Waele M, Thielemans K, Van Camp B. Detection of monoclonal B lymphocytes in bone marrow and peripheral blood of multiple myeloma patients by immunoglobulin gene rearrangement studies. Br J Haematol 1989;73:289-295.
11. Berenson J, Wong R, Kim K, Brown N, Lichtenstein A. Evidence for peripheral blood B lymphocyte but not T lymphocyte involvement in multiple myeloma. Blood 1987;70:1550-1553.
12. Bakkus MH, Heirman C, Van Riet I, Van Camp B, Thielemans K. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 1992;80:2326-2335.
13. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91:3-21.
14. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996;272:60-66.
15. Paget S. Distribution of secondary growths in cancer of the breast. Lancet 1889;1:571-573.
16. Watson ML. Chemokines-linking receptors to response. Immunology 2002;105:121-124.
17. Mellado M et al. Chemokine receptor homo- or heterodimerization activates distinct signaling pathways. EMBO J 2001;10:2497-2507.
18. Curnock AP, Logan MK, Ward SG. Chemokine signalling: pivoting around multiple phosphoinositide 3-kinases. Immunology 2002;105:125-136.
19. Vanderkerken K, et al. Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BlKaLwRij mouse. Br J Cancer 2000;82:953-959.
20. Vanderkerken K, et al. Monocyte chemoattractant-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells. Clin Exp Metastasis 2002;19:87-90.
21. Stauder R, et al. Different CD44 splicing patterns define prognostic subgroups in multiple myeloma. Blood 1996;88:3101-3108.
22. Van Driel M, Gunthert U, Stauder R, Joling P, Lokhorst HM, Bloem AC. CD44 isoforms distinguish between bone marrow plasma cells from normal individuals and patients with multiple myeloma at different stages of disease. Leukemia 1998;12:1821-1828.
23. Asosingh K, et al. In vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells. Cancer Res 2000;60:3096-3104.
24. Asosingh K, Günthert U, De Raeve H, Van Riet I, Van Camp B, Vanderkerken K. A unique pathway in the homing of murine multiple myeloma cells: CD44v10 mediates binding to bone marrow endothelium. Cancer Res 2001;61:2862-2865.
25. Vande Broek I, Vanderkerken K, De Greef C, Asosingh K, Van Camp B, Van Riet I. The high affinity 67 kD laminin receptor is expressed by multiple myeloma cells and mediates cell migration. Br J Cancer 2001;85:1387-1395.
26. Cheung WC, Van Ness B. Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells. Leukemia 2002;16:1182-1188.
27. Rowley M, Liu P, Van Ness B. Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan. Blood 2000;96:3175-3180.
28. Hardin J, et al. Interleukin-6 prevents dexame-thasone-induced myeloma cell death. Blood 1994;84:3063-3070.
29. Georgii-Hemming P, Wiklund HJ, Ljunggren O, Nilsson K. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood 1996;88:2250-2258.
30. Matrisian LM. The matrix-degrading metalloproteinases. BioEssays 1992;14:455-463.
31. Aoudjit F, Potworowski EF, St-Pierre Y. Bi-directional induction of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 during T lymphoma/endothelial cell contact: implication of ICAM-1. J Immunol 1998;160:2967-2973.
32. Owen CA, Campbell EJ. Neutrophil proteinases and matrix degradation. The cell biology of pericellular proteolysis. Semin Cell Biol 1995;6:367-376.
33. Chen WT. Membrane proteases: roles in tissue remodeling and tumour invasion. Curr Opin Cell Biol 1992;4:802-809.
34. Van Valckenborgh E, et al. Upregulation of matrix metalloproteinase-9 in murine 5T33 multiple myeloma cells by interaction with bone marrow endothelial cells. Int J Cancer 2002;101:512-518.
35. Vacca A, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999;93:3064-3073.
36. Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 1993;7:1434-1441.
37. Noël A, et al. Emerging roles for proteinases in cancer. Invasion Metastasis 1997;17:221-239.
38. Nykjaer A, et al. Recycling of the urokinase receptor upon internalization of the uPA: serpin complexes. EMBO J 1997;16:2610-2620.
39. Asosingh K, et al. Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine model of myeloma. Clin Exp Metastasis 2002;19:583-591.
40. Menu E, Braet F, Timmers M, Van Riet I, Van Camp B, Vanderkerken K. Measurement of F-actin content in multiple myeloma is a useful tool to study their migration. Ann New York Acad Sci 2002;973:124-135.
41. Vanderkerken K, Asosingh K, Braet F, Van Riet I, Van Camp B. Insulin-like growth factor-I acts as a chemoattractant factor for 5T2 multiple myeloma cells. Blood 1999;93:235-241.
42. + murine myeloma cells: involvement of LFA-1 mediated homotypic cell-cell adhesion. Exp Hematol 2003;31:48-55.
43. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 1990;50:6130-6138.
44. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature, 2001;411:375-379.
45. Hata H, Xiao H, Petrucci MT, Woodliff J, Chang R, Epstein J. Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells. Blood 1993;81:3357-3364.
46. Joshua D, Petersen A, Brown R, Pope B, Snowdon L, Gibson J. The labelling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis. Br J Haematol 1996;94:76-81.
47. +) 5T multiple myeloma cells. Exp Hematol 2001;29:77-84.
48. Asosingh K, De Raeve H, Van Riet I, Van Camp B, Vanderkerken K. Multiple myeloma tumor progression in the 5T2 murine model is a multi-stage and dynamic process of differentiation, proliferation, invasion and apoptosis. Blood 2003 (in press).
49. Mahmoud MS, Ishikawa H, Fujii R, Kawano MM. Induction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6. Blood 1998;92:3887-3897.
50. Fujii R, Ishikawa H, Mahmoud MS, Asaoku H, Kawano MM. MPC-1-CD49e- immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas. Br J Haematol 1999;105:131-140.
51. Kong YY, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
52. Lacey DL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
53. Burgess TL, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999;145:527-538.
54. Tsuda E, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997;234:137-142.
55. Simonet WS, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
56. Vanderkerken K, Asosingh K, Van Camp B, Croucher P. Anti-tumor effect of recombinant OPG in the murine 5T33MM model. Blood 2001;98:637a.
57. Vanderkerken K, et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 2003;63:287-289.
58. Radl J, et al. Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma. Cancer 1985;55:1030-1040.
59. Croucher PI, et al. Zoledroinc acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Mineral Res 2003 (in press).
60. Croese JW, Zurcher C, van den Enden-Vieveen MHM, Radl J. Effect of long-term treatment with the bisphosphonate APD on 5T2 mouse multiple myeloma. In: Radl J, Van Camp B, eds. Monoclonal Gammapathies III - Clinical Significance and Basic Mechanisms. Topics in Aging Research in Europe, vol. 14. Leiden: EURAGE, 1991;239:199-203.
61. Bakkus MH, Van Riet I, Van Camp B, Thielemans K. Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br J Haematol 1994;87:68-74.
62. Billadeau D, Ahmann G, Greipp P, Van Ness B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 1993;178:1023-1031.
63. Bakkus MH, et al. Myeloma isotype-switch variants in the murine 5T myeloma model: evidence that myeloma IgM and IgA expressing subclones can originate from the IgG expressing tumor. Leukemia 2001;15:1127-1132.
64. Bakkus MH, Van Riet I, De Greef C, Van Camp B, Thielemans K. The clonogeinc precursor cell in multiple myeloma. Leuk Lymphoma 1995;18:221-229.